Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors

See allHide authors and affiliations

Science Immunology  09 Dec 2016:
Vol. 1, Issue 6, eaaj1879
DOI: 10.1126/sciimmunol.aaj1879

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

RSV antibodies in profile

Respiratory syncytial virus (RSV) causes cold-like symptoms in healthy adults but can have serious complications in both the very young and elderly. No vaccine is approved for RSV, and although a prophylactic antibody, palivizumab, is available for high-risk infants, therapy is generally supportive. Now, Gilman et al. profile the human antibody response to the RSV fusion (F) glycoprotein. They find that the response is broad but that more potent antibodies tend to target the apex of the prefusion conformation of RSV F, suggesting this site as a putative vaccine target. Moreover, many of these antibodies were more potent than palivizumab and some cross-neutralized human metapneumovirus, making them candidates for new passive prophylactics.